Enspryng Injection, Solution
Product Images NDC 50242-007

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Enspryng (NDC 50242-007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Enspryng 01)

A Kaplan-Meier survival curve chart depicting the proportion of patients relapse free over time (weeks) for two groups: Placebo (N=23) and ENSPRYNG (N=41). The chart shows ENSPRYNG maintained a higher relapse-free proportion (76.5%) at week 96 compared to placebo (41.1%). It includes risk reduction, hazard ratio, and censored data points. Patient numbers at risk for each time point are shown in a table below the graph.*

FDA Label Image

Figure 2 (Enspryng 02)

A Kaplan-Meier survival curve graph depicting proportion relapse-free over time in weeks for two groups: ENSPRYNG (solid line) and placebo (dashed line), each with 26 patients. The chart shows significantly higher relapse-free survival for ENSPRYNG at 96 weeks (91.1%) compared to placebo (56.8%). The graph includes censored data markers and a patient risk table below the x-axis.*

FDA Label Image

Image (Enspryng 03)

An instructional diagram showing four sequential steps or items, including a square-shaped item resembling a pad, a cotton ball or similar soft material, a square gauze, and an adhesive bandage, followed by a sharp disposal container with a slot on top and a label area. This likely illustrates steps related to subcutaneous injection care and sharps disposal.*

FDA Label Image

Figure A (Enspryng 04)

Illustration showing the labeled parts of a syringe intended for subcutaneous injection, with components including needle cap, barrel, expiration date, activation guards labeled as 'Do not touch,' and plunger.*

FDA Label Image

Figure B (Enspryng 05)

An instructional illustration showing a subcutaneous injection device with a needle shield extended and locked in place. The diagram highlights the needle shield feature for safe use, likely related to Enspryng (Satralizumab) injection administration.*

FDA Label Image

Figure C (Enspryng 06)

An instructional illustration showing how to check the expiration date and seal of a medication carton. It directs the user to check the expiration date on the back and verify that the carton is sealed with a lock icon indicating the sealed area.*

FDA Label Image

Figure D (Enspryng 07)

An instructional diagram showing an open flat box packaging, with an upward arrow indicating the opening direction of the box.*

FDA Label Image

Figure E (Enspryng 08)

An illustration showing the opening of a product carton with an arrow pointing to a hand holding a prefilled syringe. The syringe is being held with the thumb press area visible, indicating how to handle the injection device for subcutaneous use.*

FDA Label Image

Figure F (Enspryng 09)

Illustration showing a hand holding a syringe filled with liquid. It includes reminders to check the expiration date, inspect the liquid inside, and check the syringe for any damage before use. An eye icon emphasizes visual inspection.*

FDA Label Image

Figure G (Enspryng 10)

Illustration showing a clock-like circle with half shaded and an arrow indicating a clockwise rotation, accompanied by text "30 min" below. This likely represents a 30-minute time instruction or duration.*

FDA Label Image

Figure H (Enspryng 11)

An instructional illustration showing two hands being washed under running water with soap lather, emphasizing proper handwashing technique.*

FDA Label Image

Figure I (Enspryng 12)

An illustration showing recommended injection site areas on the human body for subcutaneous administration. Highlighted regions include the abdomen around the navel area and the front of the thighs. The diagram is labeled 'Injection site areas.'*

FDA Label Image

Figure J (Enspryng 13)

An instructional line drawing showing a hand using a cloth or wipe to clean or prep the skin, likely demonstrating a step in the preparation for a subcutaneous injection.*

FDA Label Image

Figure K (Enspryng 14)

An instructional illustration showing a person removing a cap from the needle of a syringe held in the other hand. The syringe appears designed for subcutaneous injection, consistent with Enspryng (satralizumab) injection use instructions.*

FDA Label Image

Figure L (Enspryng 15)

An instructional illustration showing a hand holding a syringe for subcutaneous injection into the skin. A smaller inset diagram shows acceptable injection angles at 45 and 90 degrees with "OK" noted, guiding proper injection technique.*

FDA Label Image

Figure M (Enspryng 16)

An instructional illustration showing how to operate a prefilled injection device. The left side depicts a hand pressing down the plunger, indicated by a downward arrow. The right side shows a finger pressing the top of the device, with lines indicating activation or engagement of the mechanism.*

FDA Label Image

Figure N (Enspryng 17)

Instructional illustration showing two steps for using an injection device. The first step depicts pulling the cap or cover straight up to remove it. The second step shows pressing the plunger or activation button on the injection device, with indications of activation marks around the plunger area.*

FDA Label Image

Figure O (Enspryng 18)

An instructional illustration showing the disposal of a syringe into a sharps disposal container, depicting safe injection waste handling.*

FDA Label Image

Principal Display Panel (120 mg/mL Syringe Carton)

Enspryng (satralizumab-mwge) injection, 120 mg/mL, is shown on a label for a single-dose prefilled syringe intended for subcutaneous use. The label includes storage instructions, an attention note to pharmacists regarding the enclosed Medication Guide, and is marked for prescription use by Genentech, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.